Comparison of cardiovascular outcomes (repeated infarction, infarct size, hemorrhage, and death) of intracoronary abciximab or intravenous eptifibatide administration during percutaneous coronary intervention of ST-segment elevation myocardial infarction

Cardiovascular Research Center, Shahid Beheshti University of Medical sciences0 个研究点目标入组 40 人开始时间: 待定最近更新: 2018年2月22日

适应症

试验速览

暂无简介。

•ST elevation myocardial infarction (MI)
•Exclusion criteria: patients presenting with ST-elevation myocardial infarction after 12 hours from symptoms onset; patients presenting with vasospastic angina (determined by resolution of ST segment elevation, and relief of symptoms after intravenous administration of nitroglycerin); patients presenting with non-ST elevation MI; contraindications for antiplatelets such as bleeding disorder including gastrointestinal bleeding, hematuria, or any known bleeding tendency either inherited or acquired; thrombocytopenia (Platelet count less than 100.000 per microliter; recent (less than 6 months) stroke; intracranial hemorrhage at any time in patient's life or any known intracranial malformation; cardiogenic shock; left bundle branch block changes on ECG.

发起方

Cardiovascular Research Center, Shahid Beheshti University of Medical sciences